Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Proteostasis surges as FDA grants Breakthrough Therapy Designation its cystic fibrosis treatment

Tuesday, March 13, 2018 8:57
% of readers think this story is Fact. Add your two cents.

Proteostasis Therapeutics Inc (NASDAQ:PTI) was the top riser on Wall Street after the small cap biopharma’s cystic fibrosis treatment was granted  Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration.

A BTD helps to expedite the development and review of a drug aimed at treating a serious or life-threatening  diseases where there is significant unmet need and where clinical evidence has shown the drug may offer substantial improvement over existing therapies.

Strong phase II data

“We believe the Breakthrough Therapy Designation for PTI-428 reflects the strength of the recent Phase 2 study results for our amplifier, a novel and proprietary class of CFTR modulators,” said President and chief executive Meenu Chhabra.

PTI-428 is Proteostasis’ most advanced candidate and is part of a class of treatments called cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

When working normally, the CFTR protein regulates the proper flow of water and chloride in and out of the cells lining the lungs and other organs.

In people with cystic fibrosis though, mutations in the CTFR gene mean a defective protein, or no protein at all, is produced. That leads to a build-up of sticky mucus which can in turn cause infections in the lungs and damage to the pancreas.

Part of a potential triple combo therapy

CFTR modulators work by correcting the malfunctioning protein made by these CFTR-mutated genes, preventing the mucus from building up in the first place.

A recent phase II study showed that PTI-428 did indeed help to boost the levels of CFTR proteins in cystic fibrosis patients.

Proteostasis hopes the drug can be added to current and future treatments to improve lung function in those patients.

That said, the Massachusetts-based company is also developing its own triple combination regime.

Shares jumped 58.6% to US$6.57.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories


Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.